Cover Image
Read Now

Clinical review report: Riociguat (Adempas)

The objective of this systematic review is to evaluate the beneficial and harmful effects of riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg tablets for the treatment of pulmonary arterial hypertension in adults (World Health Organization [WHO] functional class II or III)

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health December 2015, 2015
Series:CADTH common drug review
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01126nam a2200229 u 4500
001 EB002010834
003 EBX01000000000000001173733
005 00000000000000.0
007 tu|||||||||||||||||||||
008 220201 r ||| eng
245 0 0 |a Clinical review report: Riociguat (Adempas)  |h Elektronische Ressource 
246 3 1 |a Riociguat (Adempas) 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c December 2015, 2015 
300 |a 1 PDF file (74 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK538670  |3 Volltext 
082 0 |a 700 
520 |a The objective of this systematic review is to evaluate the beneficial and harmful effects of riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg tablets for the treatment of pulmonary arterial hypertension in adults (World Health Organization [WHO] functional class II or III) 

Similar Items